Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02917928




Registration number
NCT02917928
Ethics application status
Date submitted
19/09/2016
Date registered
28/09/2016

Titles & IDs
Public title
The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health
Scientific title
The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health in Patients With Prediabetes and Type 2 Diabetes: a Randomsied, Double-blinded, Placebo-controlled Trial
Secondary ID [1] 0 0
16061AI
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Poor Glycemic Control 0 0
Cardiovascular Risk Factors 0 0
Cognitive Function 1, Social 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - carnosine
Treatment: Drugs - Placebo

Active comparator: Intervention - Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks

Placebo comparator: Control - Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks


Treatment: Other: carnosine
Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks

Treatment: Drugs: Placebo
Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in Oral Glucose Tolerance Test
Timepoint [1] 0 0
baseline and 14 weeks
Secondary outcome [1] 0 0
Change in HbA1c
Timepoint [1] 0 0
baseline and 14 weeks
Secondary outcome [2] 0 0
Change in lipid profile
Timepoint [2] 0 0
baseline and 14 weeks
Secondary outcome [3] 0 0
Change in systolic and diastolic blood pressure
Timepoint [3] 0 0
baseline and 14 weeks
Secondary outcome [4] 0 0
Change in arterial stiffness and central blood pressure
Timepoint [4] 0 0
baseline and 14 weeks
Secondary outcome [5] 0 0
Change in markers of endothelial dysfunction
Timepoint [5] 0 0
baseline and 14 weeks
Secondary outcome [6] 0 0
Change in heart rate variability
Timepoint [6] 0 0
baseline and 14 weeks
Secondary outcome [7] 0 0
Change in interleukins
Timepoint [7] 0 0
baseline and 14 weeks
Secondary outcome [8] 0 0
Change in tumour necrosis factor a
Timepoint [8] 0 0
baseline and 14 weeks
Secondary outcome [9] 0 0
Change in macrophage migration inhibitory factor
Timepoint [9] 0 0
baseline and 14 weeks
Secondary outcome [10] 0 0
Change in plasma C- reactive protein
Timepoint [10] 0 0
baseline and 14 weeks
Secondary outcome [11] 0 0
Change in plasma and urinary advanced glycation end products
Timepoint [11] 0 0
baseline and 14 weeks
Secondary outcome [12] 0 0
Change in plasma and urinary advanced lipoxidation end products
Timepoint [12] 0 0
baseline and 14 weeks
Secondary outcome [13] 0 0
Change in general cognitive function
Timepoint [13] 0 0
baseline and 14 weeks

Eligibility
Key inclusion criteria
* Age >=18 or <=70 years
* Weight change < 5 kg in last 6 months
* HbA1c level <= 8%
* Patients with prediabetes (Impaired glucose tolerance and impaired fasting glycaemia) or type 2 diabetes (diet controlled or on oral therapy)
* Patients will have to be on oral therapy for diabetes (without changes in treatment) at least for 3 months.
* Patients will be advised not to change their pre-existing therapy for diabetes and cardiovascular risk factors for the duration of the study if HbA1c is not above 8%
* No recent blood transfusion (3 months)
* No current intake of anti-inflammatory medications and supplements
* No significant kidney, cardiovascular, haematological, respiratory, gastrointestinal, or central nervous system disease, as well as no psychiatric disorders, no active cancer within the last five years; no presence of acute inflammation (by history, physical or laboratory examination)
* Pregnant or lactating
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Age <18 or > 70 years
* HbA1c level of >= 8%
* Weight change > 5 kg in last 6 months
* Morbid obesity (body mass index >40 kg/m2)
* Current smoking habit and high alcohol use
* Patients on insulin
* Taking anti-inflammatory medications or supplements
* Recent blood transfusion history
* Kidney (estimated glomerular filtration rate < 30 ml/min), cardiovascular, haematological, respiratory, gastrointestinal, or central nervous system disease, as well as psychiatric disorder, active cancer within the last five years; presence of acute inflammation (by history, physical or laboratory examination)
* Pregnancy or lactation

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
UNKNOWN
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/07/2023
Actual
Sample size
Target
40
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Monash Centre for Health Research and Implementation - Melbourne
Recruitment postcode(s) [1] 0 0
3168 - Melbourne

Funding & Sponsors
Primary sponsor type
Other
Name
Monash University
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Barbora de courten, MD,PHD,MPH
Address 0 0
Monash University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Barbora de Courten, MD,PHD,MPH
Address 0 0
Country 0 0
Phone 0 0
+61 385722651
Fax 0 0
Email 0 0
barbora.decourten@monash.edu
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT02917928